Allogene’s Cema-Cel Shows Early Promise in LBCL Trial — Allogene Therapeutics, Inc.

Event summary

Allogene’s Cema-Cel achieved 58.3% MRD negativity in Phase 2 ALPHA3 trial, vs. 16.7% in observation arm.
FDA granted RMAT and Fast Track designations for Cema-Cel as 1L consolidation therapy in LBCL.
ALLO-329 autoimmune disease trial enrollment progressing rapidly; clinical update expected Q4 2026.
Company ended Q2 2026 with $423.6M in cash, projecting runway into 2029.

The big picture

Allogene’s Phase 2 data suggests Cema-Cel could redefine CAR T therapy delivery, moving treatment earlier in LBCL and expanding access to outpatient settings. The RMAT designation underscores FDA’s interest in MRD-guided approaches for high-risk patients. If successful, this strategy could challenge autologous CAR T dominance while validating Allogene’s allogeneic platform.

What we're watching

Trial Execution: Whether Allogene can sustain accelerated site activation and enrollment momentum in ALPHA3 trial.
Regulatory Pathway: How FDA’s RMAT designation may influence Cema-Cel’s commercialization strategy for LBCL.
Autoimmune Expansion: The pace at which ALLO-329 data could position Allogene in the competitive autoimmune disease space.